# Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failur

Source: https://onco.cc/trials/nct06970782/  
OnCo record `nct06970782` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of vebreltinib and pemetrexed in lung cancer, run by Avistone Biotechnology Co., Ltd., not yet recruiting.

## Summary

Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure is a phase 3, randomised interventional study registered as NCT06970782 by Avistone Biotechnology Co., Ltd., with a registry enrolment figure of 278 participants, started 2025-05-15 and due to reach its primary completion in 2027-12-31. Interventions recorded: Vebreltinib; PLB1004; Pemetrexed plus Carboplatin or Cisplatin. Conditions listed: Non-Small-Cell Lung Cancer. Primary outcome: Progression-Free Survival (PFS) by BICR. Lung eligibility wording from the registry: "Histologically or cytologically confirmed locally advanced or metastatic NSCLC (stage IIIB\~IV)". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Also known as: KYLIN-3
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06970782
- Phase: 3
- Setting: A Randomized, Controlled, Open Label, Multicenter Phase III Study to Evaluate the Efficacy and Safety of Vebreltinib in Combination With PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFR Mutations, MET Amplification and/or Overexpression, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Following EGFR-TKI Treatment Failure
- Sponsor: Avistone Biotechnology Co., Ltd.
- Enrolled: 278

## Sources

- ClinicalTrials.gov NCT06970782: https://clinicaltrials.gov/study/NCT06970782

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/), [MET exon 14 and MET-amplified non-small-cell lung cancer](https://onco.cc/cancers/met-altered-nsclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Pemetrexed](https://onco.cc/drugs/pemetrexed/), [Vebreltinib](https://onco.cc/drugs/vebreltinib/)
- companies: [Avistone Biotechnology](https://onco.cc/companies/avistone-biotechnology/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06970782.json